Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
Elaine Chiquette,1 Peter P Toth,2 Gilbert Ramirez,3 Michael Cobble,4 Robert Chilton51Amylin Pharmaceuticals, San Diego, CA, 2University of Illinois, Peoria, IL, 3Florida International University, Miami, FL, 4Atherotech, Birmingham, AL, 5University of Texas, San Antonio, TX, USABackground: Dyslipidem...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-11-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/treatment-with-exenatide-once-weekly-or-twice-daily-for-30-weeks-is-as-a11499 |